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Introduction:  Stage III melanoma, also referred to as regional metastatic melanoma, has five-year 
survival rates ranging between 40% and 78%. In order to reduce the likelihood of recurrence in this 
high-risk population, patients undergo resection of primary tumors and all involved nodal basins. 
Systemic therapy is being pursued in an effort to improve outcome data, but the best strategy has yet 
to be defined. Interferon alpha-2b remains to date the most   promising approach available. Toxicities 
and intensive intravenous administration, unfortunately, are major   concerns. An alternative is the 
use of interferon in its pegylated subcutaneous form. The aim of this research was to review the 
evidence for the use of pegylated interferon alpha-2b in Stage III malignant melanoma.
Evidence review: ECOG 1684 was the pivotal trial that first demonstrated a statistically 
  significant benefit in relapse-free and overall survival for adjuvant interferon alpha-2b in high-risk 
melanoma. Other larger studies, such as ECOG 1690, confirmed a relapse-free survival benefit 
but did not achieve statistical significance for overall survival. The first study of the pegylated 
form of interferon alpha-2b in Stage III melanoma, EORTC 18991, is reviewed here. This trial 
showed a statistically significant improvement in relapse-free survival but not overall survival. 
Encouraging data of potential equivalent efficacy, easier administration, and fewer Grade 3 and 
4 adverse reactions compared with high-dose intravenous interferon raises the question of its 
potential role in Stage III melanoma in the adjuvant setting.
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Core  evidence  clinical  impact  summary  for  peg-interferon  alfa-2b  versus 
observation in Stage III malignant melanoma
Outcome measure Evidence Implications
Disease-oriented evidence
Progression-free 
survival
Hazard ratio 0.82  
P = 0.01
Statistically significant improvement in 
four-year relapse-free  
survival in patients on pegylated interferon 
compared with observation alone  
(45.6% versus 38.9%)
Overall survival Hazard ratio 0.98  
P = 0.78
No statistically significant impact of pegylated 
interferon alpha 
compared with observation alone on overall 
survival (56.8% versus 55.7%)
Patient-oriented evidence
Safety and tolerability 31% of patients discontinued 
treatment because of 
toxicities
Likely compares favorably with high-dose iv 
interferon
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Figure 1 Survival curve from the American Joint Committee on Cancer Melanoma 
Staging Database comparing different Stage iii groupings. Balch CM, Gershenwald 
JE, Soong S, et al. J Clin Oncol. 2009;27(36):6199–6206. Reprinted with permission. 
© 2008 American Society of Clinical Oncology. All rights reserved.
(Continued)
Outcome measure Evidence Implications
Quality of life 
assessment
Decreased with treatment Likely compares favorably with high-dose iv 
interferon
Economic evidence
Cost-effectiveness Not available
Cost per QALY Not available
Abbreviations: iv, intravenous; QALY, quality-adjusted life year.
Introduction
Stage III melanoma, also referred to as regional metastatic 
melanoma, includes patients with clinical Stage I or II disease 
who are found to have positive sentinel lymph node involve-
ment, or clinical Stage III disease based on the presence of 
palpable nodes without evidence of distant metastasis.1 The 
7th edition (2009) of the melanoma staging system accord-
ing to the American Joint Committee on Cancer specifies 
that nodal   metastases must be looked for with at least one 
melanoma-associated marker (for example, HMB-45, Melan-
A, MART-1) unless diagnostic cellular morphology is   present. 
It also states that even tumor deposits of isolated cells less than 
0.1 mm that meet the above criteria of immunologic staining 
are also scored as N+ and not N0 disease (see Table 1).1
This staging system is based on the database analysis of 
30,946 patients, of whom 3307 were Stage III. Depending on 
the extent of nodal involvement (micro- versus macrometa-
static nodes, number of nodes involved, or presence of in-transit 
metastases), this stage is further subcategorized into stages 
IIIA, IIIB, and IIIC, with five-year survival rates of 78%, 59%, 
and 40%, respectively (P , 0.0001) (see Figure 1).1
In order to improve outcome data and to reduce 
  recurrence risk for Stage III melanoma beyond complete 
lymph node dissection of all involved nodal basins, several 
efforts have been attempted, including adjuvant chemo-
therapy using   dacarbazine or nonspecific immune adjuvants, 
like the Bacillus Calmette-Guerin vaccine and other experi-
mental vaccines.2 Unfortunately, large randomized trials 
have failed to support their use in this clinical situation.2
Encouraging data do exist for the use of interferon (IFN) 
alpha (IFNa) and, to date, this remains the only systemic therapy 
available and approved by the US Food and Drug Administra-
tion (FDA), although much discussion about its risks and poten-
tial benefits persist. Here we examine first the initial landmark 
studies that used IFNa in locally advanced melanoma. We then 
focus the review on the use of IFNa in its pegylated form as an 
adjuvant treatment of Stage III melanoma.
Interferon alpha
Interferons are pleiotropic cytokines with antiviral, immunomod-
ulatory, and antiangiogenic effects. They inhibit viral replication 
within host cells, activate immune cells such as macrophages and 
natural killer cells, and upregulate   antigen presentation to lym-
phocytes.3 Their use in oncology   proliferated early in the 1980s, 
with some efficacy observed for different malignancies, includ-
ing hairy cell leukemia, Kaposi’s sarcoma, chronic myelogenous 
leukemia, and renal cell carcinoma.3 Single-agent recombinant 
IFNa was evaluated for metastatic melanoma in Phase I and II 
trials, with objective response rates of 16%, and about one-third 
of these being complete.3,4 In the adjuvant setting, IFNa has been 
  formally evaluated in several large cooperative group trials, in 
the hope of identifying the benefits of the immunomodulatory 
effects of IFNa on micrometastases that would translate into 
relapse-free survival (RFS) and overall survival (OS).
ECOG 1684
The Eastern Cooperative Oncology Group (ECOG) 1684 
trial was a prospective, randomized, controlled trial of 
high-dose IFNa-2b (HDI) versus observation in high-risk Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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Table 1 7th Edition (2009) AJCC melanoma staging and classification
TNM staging categories
Classification Thickness (mm) Ulceration/mitoses
Tis Not applicable Not applicable
T1 #1 a.   without ulceration  
and mitosis ,1/mm2 
b.   with ulceration or  
mitosis $1/mm2
T2 1.01–2 a. without ulceration  
b. with ulceration
T3 2.01–4 a. without ulceration  
b. with ulceration
T4  4 a. without ulceration  
b. with ulceration
N Number of  
metastatic nodes
Nodal metastatic  
burden
N0 0 Not applicable
N1 1 a. Micrometastasis  
b. Macrometastasis
N2 2–3 a. Micrometastasis  
b. Macrometastasis  
c.   in transit metastases/ 
satellites without  
metastatic nodes
N3 4+ metastatic nodes, or  
matted nodes, or in transit  
metastases/satellites with  
metastatic nodes
M Site Serum lactate  
dehydrogenase
M0 No distant metastases Not applicable
M1a Distant skin, subcutaneous  
or nodal metastases
Normal
M1b Lung metastases Normal
M1c All other visceral  
metastases
Normal
Any distant metastasis Elevated
Anatomic stage groupings for cutaneous melanoma
Clinical staging Pathologic staging
T N M T N M
0 Tis N0 M0 0 Tis N0 M0
iA T1a N0 M0 iA T1a N0 M0
iB T1b 
T2a
N0 M0 iB T1b  
T2a
N0 M0
iiA T2b 
T3a
N0 M0 iiA T2b  
T3a
N0 M0
iiB T3b 
T4a
N0 M0 iiB T3b  
T4a
N0 M0
iiC T4b N0 M0 iiC T4b N0 M0
iii Any T N . N0 M0 iiiA T1-4a  
T1-4a
N1a 
N2a
M0
iiiB T1-4b  
T1-4b  
T1-4a  
T1-4a  
T1-4a
N1a 
N2a  
N1b  
N2b  
N2c
M0
iiiC T1-4b  
T1-4b  
T1-4b  
Any T
N1b  
N2b  
N2c  
N3
M0
(Continued)
(Stage IIB and Stage III) resected melanoma that accrued 
patients between 1984 and 1990.5 In total, 287 patients entered 
the study and 280 were analyzed as the efficacy sample. Patients 
were randomized by permuted blocks within four   categories 
of clinical and pathologic extent of disease (T4N0M0, any 
TpN1M0, any TcN1M0, and any TxN1M0 recurrent) to treat-
ment with IFNa 20 MU/m2/day intravenously (IV) five days per 
week for four weeks, then three times weekly at 10 MU/m2/day 
subcutaneously (SC) for 48 weeks versus close observation.
Treatment was started within 42 days after lymphadenec-
tomy for recurrence and within 56 days after primary surgery 
and lymphadenectomy for initial presentation. Of note, at that 
time, even Stage IIB patients underwent complete regional 
lymph node dissection, which is currently not considered stan-
dard practice. However, it is also true that sentinel lymph node 
sampling was still in the process of becoming standard in this 
patient population. The primary endpoint was RFS, with the 
OS endpoint added at a later stage prior to final analysis.
One hundred and thirty-seven patients were randomized 
to the observation arm and 143 to the IFNa arm, with a similar 
distribution of patient characteristics and known prognostic 
factors between the groups. Of note, the majority of patients 
(63.5% in the observation arm and 60.8% in the IFNa arm) 
belonged to the TxN1M0 recurrent group.
After a median follow-up of 6.9 (range 0.6–9.6) years, 
median RFS was 1.72 years in the IFNa group (95% 
  confidence interval [CI] 1.07–2.88) versus 0.98 years in the 
observation group (95% CI 0.50–1.65) with a one-sided 
P value of 0.0023. RFS at five years was 37% in the   treatment 
arm versus 26% in the observation arm.
Overall median survival time was 3.82 years (95% CI 
2.34–7.08) for the IFNa group and 2.78 years (95% CI 
1.83–4.03) for the observation group, again with a significant 
one-sided P value of 0.0237. OS at five years was 46% in the 
treatment arm versus 37% in the observation arm.
There was a suggestion that the greatest benefit was obtained 
by the microscopic node-positive group, although the study was 
not powered to determine this, with only 34 patients enrolled in 
this specific category. Hazard plots suggested that the greatest 
benefits were achieved early within the first year of treatment.
Table 1 (Continued)
Anatomic stage groupings for cutaneous melanoma
Clinical staging Pathologic staging
T N M T N M
iv Any T Any N M1 iv Any T Any N M1
Balch CM, Gershenwald JE, Soong S, et al. Final version of 2009 AJCC melanoma 
staging  and  classification.  J  Clin  Oncol.  2009;27:6199–6206.1  Reprinted  with 
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Figure 2 Kaplan-Meier estimates of relapse-free survival and overall survival for patients treated in E1684 at a median follow-up of 12.6 years. Reprinted with permission 
from Kirkwood JM, Manola J, ibrahim J, Sondak v, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose 
interferon for melanoma. Clin Cancer Res. 2004;10:1670–1677. Figures 1A and 2A. © American Association for Cancer Research.
These results prompted the approval of IFNa as adjuvant 
therapy for high-risk melanoma by the FDA in 1995.
Toxicities were common, requiring dose delays or reduc-
tions in at least 37% of patients during the IV intensive phase 
and in 36% during the subsequent SC phase. Most treatment 
withdrawals secondary to toxicity happened within the first 
four months of treatment.
ECOG 1690
This Intergroup trial was designed to confirm the results of ECOG 
1684 and to compare HDI and low-dose interferon (LDI) versus 
observation in a prospective fashion.6 Again, patients were ran-
domized by permuted blocks to treatment with HDI for one year 
(20 MU/m2/day IV five days/week for four weeks then 10 MU/
m2/day SC three times a week for 48 weeks), LDI for two years 
(3 MU/m2/day SC three times a week), or observation. Eligibil-
ity criteria were the same as those described in ECOG 1684, 
although patients with normal regional lymph nodes (T4cN0M0) 
were not required to undergo staging lymph node dissection.
Strict dose modifications for toxicities were enforced, 
without attempts at dose re-escalation. Primary endpoints 
were RFS for the HDI versus LDI groups, and LDI versus 
observation groups.
With a predefined target accrual of 625 patients, the study 
enrolled 642 patients between 1991 and 1995, with 608 being 
analyzed. Baseline characteristics across treatment groups 
were comparable. As in ECOG 1684, the majority of patients 
(50.8%) belonged to the recurrent disease in regional lymph 
nodes after wide excision of primary melanoma (TxN1M0 
recurrent) group.
After a median follow-up of 4.3 years, five-year RFS 
was 44%, 40%, and 35% in the HDI, LDI, and observation 
groups, respectively. There was a significant RFS benefit 
in the HDI group compared with observation (hazard ratio 
[HR] = 1.28, P = 0.025) but not so with LDI (HR LDI/ 
observation = 1.19, P = 0.17). Five-year OS was 52%, 53%, 
and 55% in the HDI, LDI, and observation groups, respec-
tively, with no statistically significant benefit seen.Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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Figure 3 Kaplan-Meier estimates of relapse-free survival and overall survival for patients treated in E1690 at a median follow-up for 6.6 years. Reprinted with permission 
from Kirkwood JM, Manola J, ibrahim J, Sondak v, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose 
interferon for melanoma. Clin Cancer Res. 2004;10:1670–1677. Figures 1B and 2B. © American Association for Cancer Research.
Comparison of ECOG 1690 and ECOG 1684 revealed 
interesting findings. For patients randomized to the observa-
tion arms, those enrolled in ECOG 1690 enjoyed better OS 
than their ECOG 1684 counterparts (median OS 6.0 years 
in ECOG 1690 versus 2.8 years in ECOG 1684   observation 
arms). There was also an improvement in RFS in both the 
observation and treatment arms. The reasons behind these 
findings are not entirely clear. However, the authors   concluded 
that, because IFN had received FDA approval at the time of this 
study, postrelapse IFN-containing salvage therapy for patients 
in the observation arm was the main confounding factor.
Toxicities described were similar to those in the ECOG 
1684 study, with dose delays or reductions in 58% of patients 
in the HDI IV phase and in 59% of patients in the SC main-
tenance phase. No toxic deaths were reported.
Pooled analysis of Intergroup trials
The data from ECOG 1684 and ECOG 1690 were updated 
to April 2001 and reported in a pooled analysis.7 The main 
goals were to identify prognostic factors and to assess treat-
ment effects with longer follow-up.
For ECOG 1684, median follow-up was extended from 6.9 to 
12.6 years. There was still a statistical significant RFS benefit for 
HDI over observation (HR = 1.38, P = 0.02), with no statistically 
significant improvement in OS (HR = 1.22, P = 0.18) (Figure 2).
For ECOG 1690, median follow-up was extended from 4.3 
to 6.6 years. The RFS benefit of HDI over observation trended 
towards statistical significance without reaching it (HR 1.24, 
P = 0.09), and still without OS benefit (Figure 3).
Pooling data from both studies in order to compare HDI 
versus observation, a total of 713 patients were available for Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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analysis with a median follow-up of 7.2 years. Findings from 
ECOG 1690 were confirmed, with HDI having an advantage 
in terms of RFS (HR = 1.3, P = 0.006) but without a signifi-
cant OS benefit (HR = 1.08, P = 0.42) (Figure 4).
Additional data analysis
Wheatley et al presented an individual patient data meta-
analysis of all available randomized trials evaluating the role 
of adjuvant IFN in high-risk melanoma at the 2007 American 
Society of Clinical Oncology meeting.8 Event-free survival 
(EFS) and OS were assessed, and odds ratios (OR) and CIs 
calculated for patients who received IFN at various doses 
versus no IFN. In total, 6067 patients were included. In this 
individual patient data review of IFN studies, there was 
a statistically significant benefit of IFN for EFS, with an 
OR of 0.87, CI 0.81–0.93, and P value of 0.00006. It also 
demonstrated an OS survival benefit for IFN, with an OR of 
0.9, CI 0.84–0.97, and P value of 0.008. In other words, the 
absolute benefit for OS provided by IFN was statistically 
significant at 3% with a CI of 1%–5% at five years.
The most recent meta-analysis examining the effects of 
IFNa versus observation or any regimen other than IFNa in 
high-risk melanoma was presented by Mocellin et al.9 Fourteen 
randomized, controlled trials and a total of 8122 patients were 
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Figure 4 Kaplan-Meier estimates for (A) relapse-free survival and (B) overall survival by treatment for patients on E1684 and E1690 based on the updated and pooled 
analysis. Reprinted with permission from Kirkwood JM, Manola J, ibrahim J, Sondak v, Ernstoff MS, Rao U. A pooled analysis of Eastern Cooperative Oncology Group and 
intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670–1677. © American Association for Cancer Research.Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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included, with 4362 (53.7%) patients randomly assigned to the 
IFNa arm. The meta-analysis showed statistically significant 
benefit for patients who underwent IFNa treatment (HR for dis-
ease recurrence 0.82, 95% CI 0.77–0.87, P , 0.001). There was 
also a statistically significant improved OS for patients under-
going IFNa treatment (HR for death 0.89, 95% CI 0.83–0.96, 
P = 0.002). Subgroup analysis did not identify any statistically 
significant relationship between DFS or OS according to IFNa 
regimen or type, TNM disease stage, or study design.
Peg-interferon in melanoma
Pegylation involves the conjugation of a protein with 
polyethylene glycol (PEG). Following SC injection of 
such pegylated protein, rate of absorption is reduced, renal 
and cellular clearance is reduced, and the   immunogenicity 
of such protein is also reduced.10 There are currently 
two forms of pegylated IFN, mainly being used for the 
treatment of chronic viral hepatitis. Of those, pegylated 
interferon alpha-2b   (pegIFNa-2b, PEG-Intron®, Schering 
  Corporation, Kenilworth, NJ) has been the only one studied 
in melanoma.
The pharmacokinetic profile of pegIFNa-2b has been 
previously described in chronic hepatitis C patients and later 
confirmed in Phase I and II trials in oncology.10 Its long serum 
half-life of approximately 40 hours (compared with four hours 
for regular IFNa-2b) supports once-weekly administration. The 
maximum tolerated dose is 6 µg/kg/week. The safety and side 
effect profile is similar between pegylated and nonpegylated 
forms.10,11
EORTC 18991
The European Organization for Research and Treatment of 
Cancer (EORTC) 18991 was a large Phase III, randomized, 
controlled trial, the aim of which was to assess the effect 
of long-term administration of pegIFNa-2b in patients with 
resected Stage III melanoma.12 Ninety-nine centers in 17 
(mostly European) countries participated in this trial, which 
included systemic treatment-naïve, nonocular, nonmucosal 
Stage III melanoma (TxN1-2M0). Patients were random-
ized in a one-to-one ratio to treatment with pegIFNa-2b for 
five years versus observation alone. The treatment arm con-
sisted of an induction phase of pegIFNa-2b given as 6 µg/kg 
SC a week for eight weeks, followed by a maintenance phase 
of pegIFNa-2b given as 3 µg/kg SC per week for five years. 
Dose adjustments were prespecified according to toxicities 
and to maintain an ECOG performance status of 0–1. The 
primary endpoint was RFS and secondary endpoints were 
distant metastasis-free survival, OS, and safety.
In total, 1256 patients were randomized and analyzed 
based on intention-to-treat population. Both treatment and 
observation groups had comparable baseline characteristics. 
Median age was 50 years, 43% of patients had N1 disease and 
57% of patients had N2 disease. Compliance in the induction 
phase of the treatment arm was good (range of treatment 
7.3–8.0 weeks) and median duration for the maintenance 
phase was 12 (3.8–33.4) months.
After a median follow-up of 3.8 years, there was a 
  significantly improved four-year RFS for pegIFNa-2b 
compared with observation alone (45.6% versus 38.9%, 
HR = 0.82, P = 0.01). No statistical significance was reached 
for the four-year distant metastasis-free   survival (48.2% 
for pegIFNa-2b versus 45.4% for observation, HR = 0.88, 
P = 0.11) and for four-year OS rates (56.8% for pegIFNa-2b 
and 55.7% for observation groups, HR = 0.98, P = 0.78).
Kaplan-Meier curves indicated that the treatment benefit 
began early and remained throughout the study. Patient sub-
group analysis suggested that earlier disease (N1) and fewer 
numbers of lymph nodes involved showed more benefit from 
pegIFNa-2b treatment effect compared with more advanced 
disease (Figure 5).
The findings from this EORTC 18991 trial confirmed 
what has been seen with the use of standard IFNa, namely, a 
modest, statistically significant improvement in RFS, without 
such an effect for OS.
One hundred and ninety-one (31%) of the 608 patients 
who received allotted intervention in the pegIFNa-2b group 
discontinued treatment because of toxicities. The most   common 
toxicities that prompted discontinuation of treatment (without 
necessarily being Grade 3 or 4 toxicities) were fatigue (25%), 
followed by depression (16%), anorexia (15%), elevated liver 
function tests (13%), myalgias (13%), headaches (12%), nausea 
(12%), and fever (11%). Although stepwise dose reductions were 
carried out in order to maintain an ECOG performance status 
of 0–1, specific data about the number or percentage of patients 
who actually required such dose reductions was not specified.
When compared with the toxicity profiles of HDI in the 
prior ECOG 1684 and ECOG 1690 trials, the incidence of 
Grade 3 and 4 adverse events with pegIFNa-2b was less than 
with HDI. For example, Grade 3 and 4 fatigue was reported in 
16% of patients on pegIFN-2b compared with 24% of patients 
on HDI. Grade 3 and 4 myalgias affected 5% of patients on 
pegIFNa-2b, compared with 17% of patients on HDI.
Quality of life impact
While the toxicities described with the use of pegIFNa-2b in 
the EORTC 18891 study are similar to and in fact, compare 
favorably with, those of nonpegylated IFN trials, the impact Core Evidence 2010:5 submit your manuscript | www.dovepress.com
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of quality of life with pegIFNa-2b versus observation 
alone was formally addressed as a secondary endpoint 
during the EORTC 18991 study and published separately.13 
The EORTC Quality of Life Questionnaire C30 (EORTC 
QLQ-C30) used for this evaluation is a validated tool that 
is commonly used in international oncology trials.14 An 
additional nonvalidated IFNa-specific symptom checklist 
was also included. All randomly assigned patients in both 
treatment and placebo arms were included. Times of assess-
ment were at baseline, three months, 12 months, and yearly 
thereafter. The results of the study revealed a negative 
impact on global health-related quality of life for patients 
on the pegIFNa-2b arm compared with placebo. Loss of 
social functioning, appetite loss, fatigue, and symptoms 
specific to pegIFNa-2b therapy were more pronounced in 
the treatment group. Other   measurements showed a similar 
trend, losing statistical   significance after the initial three-
month evaluation.
Similar quality of life evaluations have been studied with 
different regimens involving nonpegylated IFN. HDI and 
pegIFNa-2b have not been compared head to head for quality 
of life impact. However, there is a suggestion that pegIFNa-2b 
compares favorably. Mohr et al from the   German Dermato-
logic Cooperative Oncology Group, presented   preliminary 
data of the health-related quality of life assessment in a group 
of patients receiving HDI using the same EORTC QLQ-C30 
scale at the 2007 meeting of the American Society of Clinical 
Oncology.15 The global quality of life score decreased 41% 
after the initial four weeks of IV HDI, and then an average of 
22% during the SC treatment phase.15 With the caveat of this 
being an indirect comparison of separate studies, it is inter-
esting to note that the global quality of life score in patients 
receiving pegIFNa-2b decreased 16% at three months and 
15% at two years,14 comparing favorably with HDI. No data 
for the one-month evaluation were available.
Economic impact
Cost-effectiveness studies that have looked into adju-
vant IFNa in melanoma have applied different models 
to extrapolate clinical results using the data of the dif-
ferent studies available. Such analysis has been carried 
out for the US, Canada, UK, and Spain.16–18 In general, 
the cost-  effectiveness ratios postulated range between 
US$20,000 and US$50,000 per life year gained. There 
seems to be a larger cost-effective margin for younger 
patients in more advanced stages of disease. The con-
troversy arises mostly around the data that these cal-
culations are based on.   Cost-effectiveness is favorable 
when there is an OS   advantage, something that has only 
been seen in the ECOG 1684 trial described and not so 
in the others as reviewed here. The question arises as to 
whether these cost-  effectiveness assessments represent 
a gross overestimate if no survival advantage is proven? 
Moreover, the negative impact in health-related quality 
of life experienced by patients on IFNa makes it highly 
unlikely that the intervention is favorable in terms of cost 
per quality-adjusted life year (QALY). This is illustrated 
in the most recent analysis performed by Cormier et al 
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18991. Reprinted from The Lancet, vol 372, Eggermont AMM, Suciu S, Santinami M, 
et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone 
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who quote a cost-effectiveness ranging from US$76,000 
to US$169,000 per QALY (depending on disease stage), 
crossing the historic threshold of US$100,000 per QALY 
as the cost-effective limit.16
There are no studies available addressing these same 
questions for pegIFNa-2b in the adjuvant setting for high-
risk resected melanoma. Perhaps a preliminary assumption 
might be that this is unlikely to be favorable, given that 
the EORTC 18991 study did not show an OS benefit with 
treatment, and the health-related quality of life impact 
associated with treatment was clearly detrimental. On the 
other hand, and quite importantly, the ease of administration 
and improved tolerability of pegIFNa-2b compared with 
regular IFNa provides an additional layer to be examined 
and considered within this complex problem.
Future trials and unanswered 
questions
There are two additional trials looking into the use of 
pegIFNa-2b in high-risk melanoma that have completed 
patient enrollment and are looking into improvements in 
DFS. One of them, initiated by the European Associa-
tion of Dermatologic Oncology, recruited 890 patients 
and randomized them to pegIFNa-2b 100 µg weekly for 
36 months versus IFNa 3 MU three times a week for 18 
months. The second one, initiated by the German Der-
matologic Cooperative Oncology Group, has recruited 
880 patients and randomized them to pegIFNa-2b 180 µg 
weekly for 24 months or IFNa 3 MU three times a week 
for 24 months. Outcome data for both studies are not 
available at this time.19
While there certainly are patients who benefit from treat-
ment with pegIFNa-2b, we have yet to recognize those who 
will and thus spare those who will not the significant drug 
toxicities. Markers to identify such individuals are not yet 
available, and this remains an ongoing effort in research. 
In the meantime, the current evidence behind pegIFNa-2b 
is not enough to satisfy our pursuit for more effective treat-
ment options in melanoma. However, should interferon 
be considered as “standard of care” (and it is relatively 
routinely given in the community), then the question arises 
as to whether pegIFNa-2b should also be approved, given 
the equivalent efficacy, easier administration, and possibly 
less toxicity.
Multiple trials have looked into IFN with its variations 
in route of administration, dosage, length of treatment, 
and formulations. While all of these remain important 
and necessary questions for the advancement of treating 
such a challenging disease, it also highlights the lack of 
more compelling treatment options, with a clear survival 
advantage, that patients who suffer from this terrible illness 
so desperately need.
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